DOCSLIB.ORG

Welldynerx 2021 Universal Formulary List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Welldynerx 2021 Universal Formulary List The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. In addition to using this list, you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. PLEASE NOTE: Brand name drugs may move to nonformulary status if a generic version becomes available during the year. Not all the drugs listed are covered by all prescription drug benefit programs; check your benefit materials for the specific drugs covered and the copayments for your prescription drug benefit program. For specific questions about your coverage, please call Open Access (2021) the phone number printed on your member ID card. A azithromycin clindamycin E gemfibrozil abirateroneQL, PA, † B clindamycin phosphate econazole nitrate GENOTROPINPA, † acetaminophen-codeine baclofen clindamycin-benzoyl ELIQUISQL gentamicin sulfate peroxideAE acyclovir benazepril ELMIRON GENVOYAQL, † clobetasol propionate adapalene-benzoyl benazepril-HCTZ EMGALITYQL, PA, † glatiramer acetateQL, PA, † peroxideAE clonazepam BETASERONQL, PA, † enalapril glimepiride ADVAIR DISKUSQL clonidine bisoprolol-HCTZ enalapril-HCTZ glipizide ADVAIR HFAQL clopidogrel bisulfate bosentanQL, PA, † ENBRELQL, PA, † glipizide ER AIMOVIGQL, PA, † clotrimazole BREO ELLIPTAQL Endometrin glipizide XL QL, PA, † AJOVY QL clotrimazole-betametha- AE QL BRILINTA sone EPIDUO FORTE GLUCAGON [INJ] albuterol HFAQL brimonidine tartrate colesevelamQL epinastine drops glyburide alendronate sodium QL QL bromfenac drops colestipol epinephrine [INJ] GLYXAMBI alfuzosin ER QL QL budesonide COMBIPATCHQL EPIPEN [INJ] guanfacine allopurinol QL QL buprenorphine-naloxone COMBIVENT RESPIMATQL erythromycin guanfacine ER alprazolam bupropion PA, † escitalopram oxalate H QL, PA, † COSENTYX ambrisentan PA, † bupropion ER (smoking CREON esomeprazole magne- HUMIRA amiodarone deterrent)QL siumQL, ST cyanocobalamin [INJ] hydralazine AMITIZAQL, PA bupropion ER (SR) estradiol cyclobenzaprine hydrochlorothiazide amitriptyline bupropion ER (XL) eszopicloneQL, ST cyproheptadine hydrocodone- acetamino- amlodipine buspirone etodolac phen D amlodipine-benazeprilST butalbital-apap-caffeineQL EUFLEXXAQL, PA, † hydrocodone-ibuprofen dalfampridine ERQL, PA, † amoxicillin butalbital-asa-caffeineQL exemestane hydrocortisone deferasiroxPA, † amoxicillin-clavulanate BYSTOLICQL, ST ezetimibeQL, ST hydromorphone DESCOVYQL, † amphetamine- C F hydromorphone ERQL dextroamphetamineAE desloratadineQL cabergoline FARXIGAQL hydroxychloroquine sulfate amphetamineQL,AE, ST dexamethasone calcitriol febuxostat hydroxyzine anastrozole diazepam carbamazepine fenofibrate micronizedQL hyoscyamine sulfate ANORO ELLIPTAQL diclofenac sodium carbidopa-levodopa finasteride I aprepitantQL dicyclomine carvedilol FLOVENT DISKUSQL ibandronate sodiumQL, PA,† aripiprazoleQL digoxin cefadroxil FLOVENT HFAQL imatinib mesylateQL, PA, † armodafinilQL, PA diltiazem ER cefdinir fluconazole IMBRUVICAQL, PA, † ARMOUR THYROID dimethyl fumarateQL, PA, † cefuroxime axetil fludrocortisone acetate indomethacin ARNUITY ELLIPTAQL diphenoxylate-atropine celecoxibQL fluorometholone ipratropium bromide ASMANEX HFAQL divalproex cephalexin fluorouracil† ipratropium-albuterol atenolol divalproex ER CEREZYMEPA, † fluoxetine irbesartan atenolol-chlorthalidone dorzolamide-timolol CETROTIDEPA, † fluvoxamine isosorbide mononitrate ER atorvastatin doxazosin mesylate CHANTIXQL folic acid isotretinoinAE ATRIPLAQL, † doxepin chlorhexidine gluconate FORTEOQL, PA, † J ATROVENT HFAQL doxycycline hyclate ciclopirox FULPHILAQL, PA, † JANUMET XRQL AUBAGIOQL, PA, † doxycycline monohydrate cinacalcetPA, † furosemide JANUMETQL azathioprine DUAVEEQL ciprofloxacin G JANUVIAQL azelaic acidAE duloxetineQL ciprofoxacin-dexametha- gabapentin JARDIANCEQL azelastine sone drops DUPIXENTQL, PA, † GAMMAGARDPA, † azelastine drops citalopramQL dutasterideQL GAMUNEX-CPA, † azelastine-fluticasoneQL clarithromycin (continued) THIS DOCUMENT LIST IS EFFECTIVE 1/1/2021 THROUGH 12/31/2021. UPDATED ON 1/1/2021. THIS LIST IS SUBJECT TO CHANGE. WellDyne.com ©2021. WellDyne® is a servicemark of WellDyneRx, LLC. K methylprednisolone oxcarbazepine REMICADEPA, † tizanidineQL ST ketoconazole metoclopramide oxybutynin REPATHAQL, PA, † tobramycin ketorolac drops metoprolol succinate ER oxybutynin ER RESTASISQL, PA tobramycin-dexamethasone ketorolac tromethamine metoprolol tartrate oxycodone REVLIMIDQL, PA, † tolterodine tartrate KOVALTRY† metronidazole oxycodone-acetamino- RINVOQQL, PA, † topiramate phenQL L MINIVELLEQL risperidone TOUJEO OXYCONTINQL labetalol minocycline ritonavirQL, † tramadol oxymorphone ERQL lactulose mirtazapine rizatriptan benzoateQL tramadol-acetaminophen OZEMPICQL, PA lamotrigine misoprostol ropinirole TRAVATAN ZST P lansoprazole modafinilQL, PA ropinirole ERQL ST trazodone pantoprazole LANTUS mometasone furoate rosuvastatin calciumQL, ST TREMFYAQL, PA, † paroxetine latanoprost MONOVISCQL, PA, † RUZURGIQL, PA, † TRESIBA QL ST peg-3350 electrolyte LATUDA montelukast solution S triamcinolone acetonide QL leflunomide morphine sulfate ER penicillin v potassium sertraline triamterene-HCTZ QL, PA letrozole MOVANTIK PENTASA sevelamer carbonate triazolam QL, † LEVEMIR mupirocin permethrin silodosin TRIUMEQ QL, PA levetiracetam mycophenolate mofetil phenazopyridine simvastatin TRULICITY QL, ST QL, PA, † QL, † levocetirizine MYRBETRIQ phenytoin SKYRIZI TRUVADA levofloxacin N pimecrolimus sodium fluoride V levothyroxine nabumetone pioglitazone sodium sulfacetamide valacyclovir QL QL,ST lidocaine viscous naltrexone polymyxin b-trimethoprim solifenacin succinate valsartan QL, PA LINZESS naproxen posaconazolePA sotalol valsartan-HCTZ QL QL QL, PA, † liothyronine naratriptan potassium chloride ER SPIRIVA HANDIHALER VENCLEXTA lisinopril neomycin-polymyxin- potassium citrate ER spironolactone venlafaxine hydrocortisone lithium SPRYCELQL, PA, † venlafaxine ER PA,† pravastatin NEUPOGEN [INJ] PA, † lithium ER prazosin STELARA verapamil ER QL, ST nifedipine ER QL QL, PA LIVALO prednisolone STIOLTO RESPIMAT VICTOZA nitrofurantoin QL QL, ST LO LOESTRIN FE prednisone SUBOXONE VIIBRYD nitroglycerin QL lorazepam pregabalinQL, ST sucralfate VIMPAT nortriptyline QL, † losartan potassium QL sulfamethoxazole- VIREAD † PREMARIN NOVOEIGHT trimethoprim PA, † losartan potassium-HCTZ PREMPROQL VIVITROL NOVOLIN 70/30 sulfasalazine QL, AE, ST loteprednol etabonate PREPOPIK VYVANSE NOVOLIN N sumatriptanQL lovastatin W prochlorperazine QL ST NOVOLIN R [INJ] SYMBICORT LUMIGAN progesterone warfarin NOVOLOG SYNJARDYQL M promethazine X-Y QL, PA, † NOVOLOG FLEXPEN SYNTHROID QL MAVYRET promethazine-codeine XARELTO NUCALAPA, † T-U MAYZENTQL, LD, PA, † XEMBIFYPA, † QL promethazine-DM NUVARING tacrolimus QL, PA meclizine propranolol XIFAXAN nystatin tadalafil (PAH)QL, PA, † medroxyprogesteroneQL XIIDRAQL, PA propranolol ER QL ST O tadalafil PA, † meloxicam QL XOLAIR QL, ST PULMICORT FLEXHALER QL olmesartan medoxomil tamoxifen citrate QL memantine pyridostigmine XULTOPHY olmesartan-HCTZQL, ST tamsulosin mercaptopurine Q Z QL olopatadine temazepam mesalamine quetiapine ERQL ST zaleplon omega-3-acid ethyl estersQL tenofovir disoproxil metformin quetiapineQL fumarateQL, † ZENPEP ondansetron metformin ERQL ZIEXTENZOQL, PA, † QL quinapril terbinafine ONETOUCH QL, ST methadone QL zolpidem ER PA, † QVAR REDIHALER terconazole OPDIVO QL methimazole R testosterone cypionate zolpidem ORILISSAQL, PA, † methocarbamol ramipril testosteronePA zonisamide ORTHOVISCQL, PA, † methotrexate QL QL ranolazine ER timolol maleate QL, AE oseltamivir methylphenidate ER REBIFQL, PA, † TIVICAYQL, † OTEZLAQL, PA, † methylphenidateQL, AE (continued) THIS DOCUMENT LIST IS EFFECTIVE 1/1/2021 THROUGH 12/31/2021. UPDATED ON 1/1/2021. THIS LIST IS SUBJECT TO CHANGE. WellDyne.com ©2021. WellDyne® is a servicemark of WellDyneRx, LLC. Examples of Non-Preferred Medications with Selected Formulary Alternatives The following is a list of some non-preferred brand-name medications with examples of selected covered formulary alternatives. This is not an all-inclusive list. Non-Preferred Medication(s) Selected Preferred Alternative(s) ACANYAPA and ONEXTONPA (clindamycin phosphate-benzoyl peroxide) clindamycin and benzoyl peroxide (separate agents) ADMELOGPA (insulin lispro) NOVOLOG ARNUITY ELLIPTAQL, ASMANEX HFAQL, ASMANEX TWISTHALERQL, FLOVENT AEROSPANPA (flunisolide) DISKUSQL, FLOVENT HFAQL, PULMICORT FLEXHALERQL, QVAR REDIHALERQL AIRDUOPA QL(fluticasone-salmeterol 55-14 mcg, 113-14 mcg, 232-14 mcg) ADVAIR DISKUSQL, ADVAIR HFAQL, BREO ELLIPTAQL, SYMBICORTQL ALLZITALPA QL (butalbital-acetaminophen 25-325 mg) and butalbital-acetaminophen butalbital-acetaminophen 50-325 mgQL 50-300 mgPA QL ALPHAGAN-P (brimonidine) brimonidine 0.15% ARNUITY ELLIPTAQL, ASMANEX HFAQL, ASMANEX TWISTHALERQL, FLOVENT ALVESCO PA (ciclesonide) DISKUSQL, FLOVENT HFAQL, PULMICORT FLEXHALERQL, QVAR REDIHALERQL AMRIXPA QL (cyclobenzaprine ER) cyclobenzaprine 5 mg, cyclobenzaprine 10 mg APIDRAPA (insulin glulisine) NOVOLOG APIDRA SOLOSTARPA (insulin glulisine) NOVOLOG AUVI-QPA QL (epinephrine solution) epinephrine 0.15 mgQL, epinephrine 0.3 mgQL, EPIPENQL, EPIPEN JRQL BASAGLARPA (insulin glargine) LANTUS, LEVEMIR, TOUJEO, TRESIBA BELSOMRAPA QL (suvorexant) zolpidem IRQL, zaleplon BONJESTAPA QL and DICLEGISPA QL (doxylamine-pyridoxine) OTC doxylamine and OTC pyridoxine BRAVELLE† PA (urofollitropin) GONAL-F†, GONAL-F RFF† BYETTAPA
Load more

Recommended publications
  • Pre Feasibility Report for Manufacturing of Apis
    Pre Feasibility Report For Manufacturing of APIs Cipla Limited Plot No. M12 & M14, Misc. Zone, Phase II, Sector III, Indore SEZ, Pithampur, District Dhar (M.P). - 454775 1 1. IDENTIFICATION OF PROJECT AND PROJECT PROPONENT: CIPLA Ltd is established in the year 1935 as a listed Public Limited Company. CIPLA is engaged in manufacturing of Bulk Drugs and Formulations of wide range of products in the form of tablets, injections, inhalers, capsules, ointment, powder, topical preparations, liquid, syrup drops, sprays, gels, suppositories etc. The company is having its registered office at Mumbai Central, Mumbai – 400 008. 80 years later, the company has become a front runner in the pharmaceutical industry, wielding the latest technology to combat disease and suffering in many ways, touching the lives of thousands the world over.The company’s products are manufactured in 25 state-of- art units. The company is having its manufacturing facilities at following locations: Locations Product Category Vikhroli- Mumbai R&D Virgonagar (Bangalore) Bulk Drugs and Formulations Bommasandra (Bangalore) Bulk Drug Patalganga Bulk Drugs and Formulations Kurkumbh Bulk Drugs and Formulations Goa Formulations Baddi Formulations Sikkim Formulations Indore Formulations The company is having well defined board of directors followed by managerial and technical team looking after entire operation. Management Council- 1. Mr. Umang Vohra - Managing Director and Global Chief Executive Officer 2. Mr. PrabirJha - Global Chief People Officer 3. Mr. KedarUpadhye - Global Chief Financial Officer 4. Dr. Ranjana Pathak - Global Head – Quality 5. Geena Malhotra - Global Head - Integrated Product Development 6. Mr. Raju Subramanyam – Global Head - Operations List of Key Executives- 1.
    [Show full text]
  • Orexin Receptor Antagonists As Therapeutic Agents for Insomnia
    REVIEW ARTICLE published: 25 December 2013 doi: 10.3389/fphar.2013.00163 Orexin receptor antagonists as therapeutic agents for insomnia Ana C. Equihua 1, Alberto K. De La Herrán-Arita 2 and Rene Drucker-Colin 1* 1 Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, México 2 Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA, USA Edited by: Insomnia is a common clinical condition characterized by difficulty initiating or maintaining Christopher J. Winrow, Merck, USA sleep, or non-restorative sleep with impairment of daytime functioning. Currently, Reviewed by: treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) Matthew R. Ebben, Weill Medical and pharmacological therapy. Among pharmacological interventions, the most evidence College of Cornell University, USA Gabriella Gobbi, McGill University, exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although Canada concerns persist regarding their safety and their limited efficacy. The use of these Matt Carter, University of hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) Washington, USA neuropeptides have been shown to regulate transitions between wakefulness and Michihiro Mieda, Kanazawa University, Japan sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the *Correspondence: development of a new class of pharmacological agents that antagonize the physiological Rene Drucker-Colin, Departamento effects of orexin. The development of these agents may lead to novel therapies for de Neurociencias, Instituto de insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed Fisiología Celular, Universidad arousal, and motor balance difficulties). However, antagonizing a system that regulates Nacional Autónoma de México, Circuito exterior S/N, Apdo.
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • OREXIN ANTAGONISTS BELSOMRA (Suvorexant), DAYVIGO (Lemborexant)
    OREXIN ANTAGONISTS BELSOMRA (suvorexant), DAYVIGO (lemborexant) RATIONALE FOR INCLUSION IN PA PROGRAM Background Belsomra (suvorexant) and Dayvigo (lemborexant) are orexin receptor antagonists used to treat difficulty in falling and staying asleep (insomnia). Orexins are chemicals that are involved in regulating the sleep-wake cycle and play a role in keeping people awake (1-2). Regulatory Status FDA-approved indication: Orexin receptor antagonists are indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (1-2). Orexin Antagonists are contraindicated in patients with narcolepsy (1-2). Orexin Antagonists are central nervous system (CNS) depressants that can impair daytime wakefulness even when used as prescribed. Medications that treat insomnia can cause next-day drowsiness and impair driving and other activities that require alertness. Orexin Antagonists can impair driving skills and may increase the risk of falling asleep while driving. People can be impaired even when they feel fully awake. Patients should also be made aware of the potential for next-day driving impairment, because there is individual variation in sensitivity to the drug (1-2). The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or mental illness that should be evaluated (1-2). Warnings and precautions that should be discussed with the patient on Orexin Antagonist therapy include adverse reactions on abnormal thinking and behavioral changes (such as amnesia, anxiety, hallucinations and other neuropsychiatric symptoms), complex behaviors (such as sleep- driving, preparing and eating food, or making phone calls), dose-dependent increase in suicidal ideation, and sleep paralysis which is the inability to move or speak for up to several minutes during sleep-wake transitions (1-2).
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
    Role of the orexin receptor system in stress, sleep and cocaine use NCT02785406 Version Date: 04/25/2017 IRB NUMBER: HSC-MS-16-0120 IRB APPROVAL DATE: 04/25/2017 Title: Role of the orexin receptor system in stress, sleep and cocaine use Principal Investigator: Scott D. Lane Co-Investigators: Joy M. Schmitz, Charles E. Green, Jin H. Yoon, Michael F. Weaver ABSTRACT Preclinical research has established important functions for the orexin system in mediating arousal/sleep, stress, and cue-induced reinstatement of drug taking (e.g., relapse). The role of stress/anxiety and drug cue reactivity in human drug relapse is well established, but to date, the role of the orexin system in modulating these phenomena has not been examined in humans with substance use disorders (e.g., cocaine). The goal of the present first-in-human study will be to examine the effects of an orexin antagonist (suvorexant) on interactions among stress/anxiety, sleep, and drug-cue reactivity. We will utilize a battery of highly sensitive, drug-specific, laboratory measures of drug cue reactivity (a relapse risk model), and well-established metrics of stress/anxiety and sleep. We hypothesize that antagonism of the orexin system will attenuate the link between (1) stress/anxiety and drug cue reactivity, and (2) sleep and drug cue reactivity. These results will elucidate a unique biochemical mechanism for understanding relapse, and provide a potential medication target for relapse prevention SCIENTIFIC IMPACT Given the promising preclinical data on the orexin system in modulating sleep, anxiety, and drug cue reactivity, this research project has high translational scientific value.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • IJBCP International Journal of Basic & Clinical Pharmacology Orexin
    Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161493 Review Article Orexin receptors: a journey through their discovery to the development of suvorexant, the new sleeping pill Anandabaskar Nishanthi*, Mourouguessine Vimal, Selvarajan Sandhiya, Steven Aibor Dkhar JIPMER, Sri Manakula Vinayagar Medical College and ABSTRACT Hospital, Puducherry, India Orexin (OX) neuropeptides acting through G-protein coupled OX1 and OX2 Received: 29 March 2016 receptors are implicated in a variety of physiological roles including regulation Accepted: 27 April 2016 of feeding, sleep-wake cycle, energy metabolism and reward pathways. Accumulating experimental evidence indicates that orexins are wake promoting *Correspondence to: neuropeptides and deficits in orexinergic neurotransmission leads to narcolepsy, Dr. Anandabaskar Nishanthi, a debilitating sleep disorder. This has led to a search for orexin receptor agonists Email: nishanthi11189 for pharmacotherapy of narcolepsy. However, development of orexin receptor @gmail.com agonists are still in their infancy stage and it invokes further research to know whether it could turn into a reality. In addition, the role of orexin neuropeptides Copyright: © the author(s), in promoting arousal and wakefulness has generated considerable interest in publisher and licensee Medip developing orexin receptor antagonists for treatment of insomnia. This quest Academy. This is an open- was accomplished with the approval of suvorexant by United States food and access article distributed under drug administration in 2014. This remarkable discovery has opened a novel the terms of the Creative approach for treatment of insomnia through neuromodulation of orexin Commons Attribution Non- signaling. Hence this review focuses on the orexinergic system, their Commercial License, which physiological action and potential role as pharmacological targets.
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • By Ron Melton, Od, and Randall Thomas, Od, Mph
    BY RON MELTON, OD, AND RANDALL THOMAS, OD, MPH Supported by an Unrestricted Grant from FC_DG0515_me.indd 4 4/27/15 3:33 PM Why Drug Costs are Skyrocketing By Agustin Gonzalez, OD drug shortage list in 2012.4,5 A tab- a price decrease while one-third let that cost as little as 6 cents early noted price increases. Only 6% of or the last few years, patients in 2012 was being retailed at $4+ the medications doubled in cost, have complained of price by November 2013—when it was and only about 12 medications and F increases and even shortages even available.5 dosages had increases in cost by 20 of some medications, which has How did this increase happen? times or more.8 frustrated many clinicians. Unfortu- The costly 12 were represented nately, price increases and inflation Reasons for the Rise as various forms and/or dosages of are a common problem affecting Analysts and politicians have cited just four molecules. The leader in everyday life, and medications are many factors—including greed, cost was doxycycline, followed by no exception.1,2 But more recently, FDA regulations and the Afford- the asthma medication albuterol. In shortages of doxycycline and the in- able Care Act—but industry experts the ophthalmic arena, doxycycline creased cost of generic prednisolone attribute price increases for these was not alone; a tube of erythro- formulations have perhaps hit eye medications to consolidation, short- mycin ointment that retailed for $4 care harder than any other medical ages in ingredients and decreased in 2012 cost more than $25 by late group.3 manufacturing.6, 7 2013.
    [Show full text]